2 cytokeratin 5/6 positivity (P = .028), and IGFBP2 expression (P = .042). High levels of IGFBP2 expression were seen in 32% of cases; independent predictors of high levels were cytokeratin 14 negativity (P = .005). PTEN loss and high levels of IGFBP2 expression were associated with poorer survival but neither of these trends was significant.
Conclusions: PTEN loss is a frequent event in triple-negative breast cancers and is significantly associated with younger age at onset of breast cancer, late stage, and IGFBP2 expression.
Triple-negative (TN) breast cancers are defined by their lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), and account for 10% to 24% of all breast cancers. [1] [2] [3] [4] Notably, TN breast cancers share many overlapping characteristics with basal-like breast cancers, in that the majority of TN breast cancers have elevated expression of high-molecular-weight cytokeratins and both have similar gene expression signatures. [5] [6] [7] [8] [9] TN tumors are predominantly high-grade and aggressive cancers with poor prognosis, and unlike hormone receptor-and HER2-positive breast carcinomas, no targeted therapeutic regimens have been shown to significantly improve survival. 10 The treatment of these tumors is therefore challenging and biomarker studies are required to better characterize these tumors with the aim of identifying improved therapeutic interventions.
Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene that is lost or mutated in many types of cancer, including breast, prostate, and lung cancer. 11 PTEN dephosphorylates PIP 3 , a product of the PI3K pathway, thereby inactivating the Akt signaling pathway, inhibiting cell growth and promoting apoptosis. 11 More recently, PTEN has been postulated to have an important role in DNA repair, because mutation or loss of PTEN results in a deficiency to repair DNA double strand breaks. 12 Although one previous study reported PTEN loss in 48% of unselected breast cancer cases, 13 other studies have reported lower incidence of PTEN loss (8%, 15%, 28%). [13] [14] [15] However, these differences may reflect methodologic differences in testing and reporting PTEN loss. In contrast, a recent study suggests that up to 66% of basal-like breast cancers have loss of PTEN, which may occur more frequently in this phenotype than in other subtypes of breast cancer. 15 Insulin-like growth factor-binding protein 2 (IGFBP2) is a member of six binding proteins that modulate the action of insulin-like growth factors (IGF-I, IGF-II) that principally signal via the type 1 IGF receptor (IGF-IR). 16 This axis plays a critical role in the development and progression of many epithelial cancers, including 3 breast cancer. 17 At the cellular level, the IGF-I receptor appears to play a fundamental role in maintaining the transformed phenotype. 18 Recent prospective epidemiologic studies have consistently shown strong associations between circulating IGF-I levels and the subsequent risk of developing a number of epithelial cancers, including breast cancer. 19 Although IGFBPs can act to either inhibit or enhance IGF-induced cell signaling, they can also exert effects in an IGF-I-independent manner, indicating that IGFBPs can intrinsically modulate aspects of cell growth and survival. 20 Busund et al 21 reported that IGFBP2 abundance was markedly higher in invasive breast carcinoma and carcinoma in situ compared with normal breast tissue or benign hyperplastic lesions that had very little IGFBP2 expression. Wang et al 22 reported that tumor expression of IGFBP2 could predict tumors most likely to metastasize. IGFBP2 clearly appears to play a role in breast cancer progression, 21,23-26 and interestingly, high levels of IGFBP2 expression have also been identified in a number of additional cancers, including prostate, 27 ovary, 28 stomach, 29 adrenal gland, 30 and bladder, 31 suggesting that IGFBP2 generally plays an important role in tumorigenesis.
An unbiased screen of human prostate and glioblastoma samples, using microarray-based expression profiling, identified IGFBP2 as the most significant marker of PTEN loss. 32 Although the mechanism of loss of expression of PTEN in breast cancer has yet to be fully elucidated in cell lines, PTEN activity is downregulated by the interaction of IGFBP2 with the 1 integrin receptor. 16 The purpose of the current study was to investigate for the first time the association between PTEN loss and IGFBP2 expression in a relatively large series of TN breast cancers and to relate this expression to basal cytokeratin expression and the clinicopathologic features of stage, histologic grade, patient age, and overall survival.
Materials and Methods

Tissue blocks of all accessible TN breast carcinomas diagnosed between 2004 and 2009 at the University of Malaya
Medical Centre (Kuala Lumpur, Malaysia) were used in this study, with a total of 101 identified as having adequate invasive tumor tissue for evaluation. All tissues had been fixed in 10% neutral-buffered formalin for 6 to 72 hours, and processed to paraffin wax blocks, from which sections were cut at 3-μm thickness on a rotary microtome and mounted onto Tissue Tek Plus glass slides (Sakura, Alphen aan den Rijn, The Netherlands) to ensure maximum adhesion.
Assessment of Tumor Grade and Stage:
Grading was performed according to the modified Bloom and Richardson criteria 33 and all slides were reviewed and regraded for this study by the histopathologists on the team. [Au3: Pls include initials] Clinical data on patient age, ethnicity, and stage (American Joint Commission on Cancer, 2003) were extracted from the database for this series of cases. Patients were staged based on criteria described in the 6th edition of the American Joint Commission on Cancer (AJCC) guidelines. 34
Immunohistochemistry
Expression of ER, PR, HER2, IGFBP2, PTEN, cytokeratins 5/6, and cytokeratin 14 was tested using standard immunohistochemical methods. Briefly, slides were deparaffinized, treated with 0.3% hydrogen peroxide to block endogenous peroxidase, and incubated for 30 minutes in a 750-W microwave oven in the appropriate antigen retrieval buffer to expose tissue antigens. The slides were then incubated in the respective primary antibodies overnight at 4C ❚ Table 1❚ . A horseradish peroxidase-conjugated avidin-biotin-based system was used for antibody detection and visualization (Vector Elite, Vector Laboratories, Peterborough, England). Nuclei were counterstained with Harris hematoxylin. The specificity of the IGFBP2 antibody was tested by adding a specific IGFBP2 blocking peptide (Santa Cruz Biotechnology, Dallas, TX) to the primary antibody mix before application. Positive cell lineblock controls for ER, PR, and HER2 were used as described previously. 35 
Assessment of Immunohistochemistry
Immunohistochemical staining for ER and PR was assessed with the Allred scoring system described in the most recent American Society of Clinical Oncology/College of American Pathologists guidelines. 36 [34%-66%], 5 [67%-100%]). The intensity and proportion scores were then summed to give a total score ranging from 0 through 8, with a score of more than 2 defined as positive for ER or PR. The same scoring system was used to assess the cytoplasmic staining of IGFBP2 in the invasive tumor compartment, with a total score of 0, 2 to 5, and (which equates to an Allred score of >5) was associated with worse breast cancer-specific survival in hormone receptor-negative disease. Positivity for HER2 was defined as intense and complete membrane staining (chicken wire pattern) of at least 30% of invasive tumor cells. 37 Most tumors were large and heterogeneous in nature with respect to PTEN expression. Consequently, PTEN expression was considered lost in cases of complete absence of staining (both cytoplasmic and nuclear) in at least two thirds of the invasive tumor compartment, with PTEN staining in the adjacent normal stromal tissue being used as the internal positive control. Cytokeratin 5/6 and cytokeratin 14 immunostaining was assessed on the basis of 10% or more invasive tumor cells showing cytoplasmic positivity, using appropriate localized staining of normal glands as positive internal controls. The basal-like phenotype was defined as positivity for cytokeratin 5/6 and/or cytokeratin 14. 8 Cases that were not possible to interpret or did not have sufficient positive control staining were omitted from analysis.
Follow-up Data
At the University of Malaya Medical Centre, all patients were followed-up via scheduled appointments in the specialist breast cancer clinics. Data on mortality were obtained from the hospitals' medical records, as well as through active follow-up. In addition, vital status was verified through direct linkage with the National Registration Department in Malaysia. Follow-up time was calculated as the interval between date of diagnosis and date of death, or date of last contact, whichever came first.
Statistical Analysis
Continuous variables (age) were described using medians and compared using the Mann-Whitney U test; categorical variables (ethnicity, stage, grade, IGFBP2 expression, PTEN loss, cytokeratin 5/6 expression, and cytokeratin 14 expression) were expressed as proportions and compared using either the  2 test or Fisher exact test. Variables significantly associated with PTEN loss and IGFBP-2 expression were simultaneously entered into a multivariate logistic regression model, with PTEN loss and IGFBP-2 as the outcome variables to determine the independent predictors of PTEN loss and IGFBP2 expression. Because information on cause of death was not available for most patients, we calculated relative survival rates (RSRs) to estimate the high mortality rate associated with breast cancer among the patient population. 36 Population mortality data for Malaysia were used to compute these estimates. The 6 relative survival rate adjusts for the general survival of the Malaysian population for the given sex, age, and year, and thus is a measure of net survival attributed to breast cancer independent of other causes of death. P values of less than .05 were considered statistically significant, as was the 95% confidence interval (CI) for odds ratio (OR) that did not include 1.0. All statistical analyses were carried out using IBM Statistics software (version 20; IBM SPSS, Armonk, NY) and Stata MP (version 14) software (StataCorp, College Station, TX). 
Results
IGFBP2
IGFBP2 staining was predominantly confined to the cytoplasmic compartment of the invasive cancer cells with little stromal staining or expression in normal glands. Addition of the IGFBP2 blocking peptide resulted in complete absence of staining in cases shown to be strongly positive for IGFBP2 ❚ Image 4❚ . Of 100 TN cases that were assessable for IGFBP2 staining, 32% showed high levels of IGFBP2 expression (Allred score >5). Univariate analysis revealed no significant differences in high IGFBP2 expression and age, stage, or cytokeratin 5/6 but IGFBP2 expression was associated with lack of staining for cytokeratin 14 (P = .004). Multivariate analysis showed that independent predictors of high levels of IGFBP2 expression were lack of positivity for cytokeratin 14 (P = .005) and PTEN loss (P = .047) ❚ Image 5❚ . There was also a trend for lymphovascular invasive cases to have high levels of IGFBP2 expression but this trend was not significant (P = .064).
Survival Analysis
TN cases with PTEN loss seem to have a poorer survival than cases without PTEN loss; the 4-year RSR for patients with PTEN loss was 65.0% (95% CI, 45.2%-79.7%) compared with 77.8% (95% CI, 60.8%-89.0%) in those without PTEN loss. Similarly, cases with high levels of IGFBP2 experienced marginally lower survival than their counterparts with low or negative IGFBP2; the 4-year RSR was 68.4% (95% C,: 44.5%-84.5%) for high levels of IGFBP2 compared with 74.9% (95% CI, 60.8%-85.1%) for cases with low or no IGFBP2 expression ❚ Figure 1❚ and ❚ Figure 2❚ .
Discussion
In the current study, PTEN expression in tumor cells is lost in nearly half of all TN breast cancers when tested using the antibody clone 6H2.1. Notably, the extent of PTEN loss in TN breast cancer is significantly higher than that reported using the same PTEN antibody in an unselected breast cancer cohort. 15 Clone 6H2.1 is the recommended marker for immunohistochemical analysis of PTEN loss because it is the only antibody that exhibits a correlation with molecular alterations in PTEN 38 and shows a correlation between western blot analysis and PTEN mutational and allelic status. 14 Loss of PTEN staining in the invasive tumor compartment is readily assessable; strong positive staining of the adjacent nontumor stroma serves as an excellent internal positive control, as previously reported. 14 Interestingly, loss of PTEN was significantly associated with a younger age at diagnosis. This reflects the findings by Anders et al 39 that PTEN expression and genes involved in related signaling pathways were altered in breast cancers that occurred in younger patients (≤45 years).
Although not significant, PTEN loss was associated with breast cancer survival; this is in agreement with the significant findings of Depowski et al 40 in a cohort of breast cancers not selected on the basis of TN status. TN cohorts generally tend to have poorer survival than unselected cohorts of breast cancer cases. Consequently, it is probably necessary to study larger TN cohorts with PTEN loss to establish whether the trend observed in the current study becomes significant when larger numbers of cases are included.
IGFBP2 positivity was associated with lymphovascular invasion and lower breast cancer survival rates. However, neither of these reached statistical significance, possibly because of the small number of cases in the current study.
These data are consistent with those of So et al, 26 who showed that of 3,117 breast tumors that were assessable for both ERα status and IGFBP2 expression, IGFBP2 was not prognostic among the ERα-positive tumors, but a trend showed lower breast cancer disease-specific survival rates in the ER-negative tumors. Furthermore, in vitro studies have demonstrated that overexpression of IGFBP2 in ER-negative breast cancer cell lines and cell lines of other cancer types that include those of prostate, glioma, and bladder conferred a growth advantage, enhanced invasion and migration, and chemoresistance. 22, 26, 31, 41 Interestingly IGFBP2 expression in tumors was linked to lack of staining for the basal cytokeratin 14. TN breast cancers are enriched for characteristics of epithelial mesenchymal transition and we speculate that these tumors may be undergoing epithelial mesenchymal transition. Further studies would be required to confirm this. A recent study showed that IGFBP2 promotes angiogenesis in neuroblastoma cells via direct activation of the vascular endothelial growth factor (VEGF) promoter 42 and anti-VEGF therapy of gliomas; infiltrating tumor was associated with increased levels of IGFBP2. 43 Because VEGF is already considered a target in TN breast cancer, perhaps cotargeting IGFBP2 might be of benefit. In addition, overexpression of EGFR and IGFBP2 has been observed in high-grade astrocytomas and coexpression of these genes was strongly associated with high-grade gliomas and lower survival. This report suggested that coexpression of these genes had a more important clinical and biological impact than the expression of each individual gene alone. 44 EGFR is strongly associated with TN breast cancer and is a potential target 45, 46 ; there may now be a rationale for assessing EGFR status in relation to IGFBP2 expression in TN breast cancers because perhaps cotargeting both of these would provide a better outcome. 9 This is the first immunohistochemical study to show an association between IGFBP-2 expression and PTEN loss and supports the evidence from studies using in vitro cell lines that show IGFBP2 downregulates PTEN 16 and conversely that overexpression of PTEN has been shown to reduce IGFBP2 expression. 47 These studies indicate IGFBP2 plays a role in the PI3K signaling pathway that is known to be involved in promoting survival and growth. 48 Several pathways could be responsible for this inverse relationship, including increased IGFBP2 expression by breast cancer cells diminishing or ablating the expression of PTEN protein, potentially via integrin receptors. 16 Further work could also investigate how IGFBP2 affects the catalytic activity of PTEN. PTEN possesses a carboxy-terminal, noncatalytic regulatory domain with three phosphorylation sites (Ser380, Thr382, and Thr383) that regulate its biological activity. 49, 50 Antibodies are available that recognize phosphorylation at these sites and may prove useful in further studies to investigate the relationship between IGFBP2 expression and PTEN phosphorylation and thus activity.
In summary, we have shown that loss of PTEN can be readily assessed using immunohistochemistry; that PTEN loss is a frequent event in TN breast cancers; and that this is significantly associated with a younger age at onset of breast cancer, late stage of presentation, and high levels of IGFBP2 expression. [Au7: Tables 4 and 5 
